Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Refining Tamoxifen Dose for Premenopausal Breast Cancer Risk Reduction (RENAISSANCE): A Phase II Single Arm Trial

NCT06184750 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT06184750
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06184750 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Refining Tamoxifen Dose for Premenopausal Breast Cancer Risk Reduction (RENAISSANCE): A Phase II Single Arm Trial
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Recruiting
Start date
September 27, 2024
Completion date
September 30, 2028
Enrollment
200 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

breast atypical ductal hyperplasia, breast atypical lobular hyperplasia, breast carcinoma, breast ductal carcinoma in situ, breast lobular carcinoma in situ, estrogen receptor-positive breast carcinoma